BIOCYTOGEN PHARMA. H YC1 Total Assets
BIOCYTOGEN PHARMA. H YC1 total assets. Based on the latest financial reports, BIOCYTOGEN PHARMA. H YC1 (I54) holds total assets worth €3.72 Billion EUR (≈ $4.35 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see I54 market cap overview for the company's overall valuation and market capitalisation.
Total Assets of BIOCYTOGEN PHARMA. H YC1 (2021–2025)
Total assets of BIOCYTOGEN PHARMA. H YC1 from 2021 to 2025. This chart illustrates how BIOCYTOGEN PHARMA. H YC1's total assets have evolved over time, based on quarterly financial data. See BIOCYTOGEN PHARMA. H YC1 share price for real-time trading data and today's change.
BIOCYTOGEN PHARMA. H YC1 - Asset Composition Analysis
BIOCYTOGEN PHARMA. H YC1 Total Assets Breakdown (December 2025)
BIOCYTOGEN PHARMA. H YC1 total assets breakdown as of December 2025. BIOCYTOGEN PHARMA. H YC1's total assets of €3.72 Billion consist of 57.7% current assets and 42.3% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 42.0% |
| Accounts Receivable | €300.14 Million | 8.1% |
| Inventory | €174.75 Million | 4.7% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €13.36 Million | 0.4% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how BIOCYTOGEN PHARMA. H YC1's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore BIOCYTOGEN PHARMA. H YC1 working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BIOCYTOGEN PHARMA. H YC1's current assets represent 57.7% of total assets in 2025, an increase from 38.0% in 2021.
- Cash Position: Cash and equivalents constituted 42.0% of total assets in 2025, up from 20.3% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 8.1% of total assets.
BIOCYTOGEN PHARMA. H YC1 Competitors by Total Assets
Key competitors of BIOCYTOGEN PHARMA. H YC1 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL LTD SPON.ADR 2
F:CSJA
|
Germany | €38.45 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
PHARVARIS N.V. EO -12
F:9EN
|
Germany | €301.45 Million |
|
NANOBIOTIX S.A. SP.ADR
F:5NRA
|
Germany | €67.76 Million |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513
|
China | CN¥3.82 Billion |
BIOCYTOGEN PHARMA. H YC1 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.31 | 1.53 | 1.34 |
| Quick Ratio | 2.12 | 1.33 | 1.17 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €1.22 Billion | €281.62 Million | €193.54 Million |
BIOCYTOGEN PHARMA. H YC1 - Advanced Valuation Insights
This section examines the relationship between BIOCYTOGEN PHARMA. H YC1's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 9.65 |
| Latest Market Cap to Assets Ratio | 0.15 |
| Asset Growth Rate (YoY) | 54.2% |
| Total Assets | €3.72 Billion |
| Market Capitalization | $545.45 Million USD |
Valuation Analysis
Below Book Valuation: The market values BIOCYTOGEN PHARMA. H YC1's assets below their book value (0.15x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: BIOCYTOGEN PHARMA. H YC1's assets grew by 54.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for BIOCYTOGEN PHARMA. H YC1 (2021–2025)
The table below shows the annual total assets of BIOCYTOGEN PHARMA. H YC1 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €3.72 Billion ≈ $4.35 Billion |
+54.20% |
| 2024-12-31 | €2.42 Billion ≈ $2.82 Billion |
-1.39% |
| 2023-12-31 | €2.45 Billion ≈ $2.86 Billion |
-12.52% |
| 2022-12-31 | €2.80 Billion ≈ $3.27 Billion |
+21.58% |
| 2021-12-31 | €2.30 Billion ≈ $2.69 Billion |
-- |
About BIOCYTOGEN PHARMA. H YC1
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of novel antibody-based drugs and pre-clinical research services in the People's Republic of China, the United States, and internationally. It operates through five segments: Gene-Editing; Pharmacological Efficacy; Model Animals; Antibody Development; and Other. The company provides th… Read more